Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading ... (deficit andhyperactivity disorder (ADHD)...)

Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal

Date:6/17/2008

deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's Web site: http://www.shire.com.

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGFB3) and velaglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD) ; Shire's ability to secure
'/>"/>

1

GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Some patients may not need insulin for long-term control of type 2 diabetes
2. New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis
3. Social Security Statement Advises Seniors to Consider Private Long-Term Care Insurance, LTC Agency Reports; Medicare Wont Cover It
4. Treatment at an AASM accredited sleep center improves long-term CPAP compliance
5. Poor sleep a problem in long-term breast cancer survivors
6. Long-term pesticide exposure may increase risk of diabetes
7. Long-term bouts with hay fever worsen ability to breathe through your nose
8. Keane Wins $1.5 Million Electronic Medical Record (EMR) Implementation with Leading Long-Term Care Company
9. Long-term hormone replacement therapy increases breast cancer risk
10. Study concludes no racial disparities in long-term outcomes in recipients of liver transplants
11. Long-term cognitive decline in bypass patients not due to surgery

Post Your Comments:

Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading ...(deficit andhyperactivity disorder (ADHD)...),Health